Sema4

Happy New Year to everyone, including all our valued customers, patients, partners, and employees. We wish you a healthy and safe 2023.

Last week we exhibited at the Hot Topics in Neonatology conference, showcasing our research and collaboration efforts, the benefits of sequencing over panel testing, & the clinical utility of sequencing in the . Learn more about our offerings: https://hubs.ly/Q01vRSVp0

A recent study we worked on with the University of Washington and Seattle Children's Hospital shows the clear benefits of rapid whole sequencing for diagnosing critically ill in the . Learn more about the results of the research: https://hubs.la/Q01vpK9p0.

sequencing is now recognized as a first-tier testing option for unexplained by the National Society of Genetic Counselors and the American Epilepsy Society. Last week, we spoke with many providers at about the benefits of genetic testing for their . Learn more about the newly endorsed guidelines: https://hubs.ly/Q01v752v0.

We have announced new research highlighting the importance of rapid sequencing for diseases in the . Our study underscores the opportunity to improve health outcomes for critically ill newborns with early medical intervention. Learn more: https://hubs.la/Q01t-rQx0.

What are the goals of the GUARDIAN study? Learn how we’ll impact the lives of 100k in and why we were selected to provide whole sequencing & interpretation services for the landmark study: https://hubs.la/Q01tkwt50.

On this , we’d like to sincerely thank our patients, customers, and partners for their support and for being at the core of our mission to deliver personalized, actionable insights. We hope you have a joyous holiday. Happy Thanksgiving!

We were proud to support the The DDX3X Foundation - Research at their annual scientific conference with members of our genetic counseling team. Our team met with families to talk about testing while learning invaluable lessons from the community. Working with organizations like DDX3X Foundation is important to increase awareness of genetic testing for diagnosing diseases. Learn more about how GeneDx connects advocates to patients in need: https://hubs.ly/Q01s-19w0.

LabPulse.com featured our recent collaboration with Massachusetts General Hospital on new research demonstrating & sequencing deliver more diagnostic certainty than multi-gene panels. Read more: https://hubs.la/Q01sBT8Y0.

Sema4|GeneDx announces collaborative study results for effectiveness of genome and exome sequencing In the study, genomic tests reported 30% fewer inconclusive results compared to multi-gene panel tests (23% vs. 33%) and a higher diagnostic yield (18% vs. 10%)